Fsd Pharma Inc. HUGE
We take great care to ensure that the data presented and summarized in this overview for FSD Pharma Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in HUGE
Top Purchases
Top Sells
About HUGE
FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.
Insider Transactions at HUGE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|